Posted April 22, 2012 Rosiglitazone, branded under Avandia and marketed as a drug to help diabetics process insulin by manufacturer GlaxoSmithKline, has been the focus of several lawsuits in the United States and Europe. Due to the reported side effects, Avandia declined in popularity and is now subject to restrictions placed by the Food and Full Article…
Search LawsuitInformation.org
Viewing 1 to 10 of 17 items
Legal Help Available as More Mothers Discover Zoloft Link to Birth Defects
Posted April 11, 2012 on PRWeb El Segundo, CA (PRWEB) April 11, 2012 Although many parents are just now learning about the birth defect risks associated with antidepressant drugs like Zoloft, the research linking these drugs to birth defects has been out for years and lawyers have already helped thousands of families affected file a Full Article…
Comments Off
Antidepressants Taken During Pregnancy And Birth Defects
Posted June 6, 2011 on Michael Shaw While this subject is by no means a new one, the resurgence of TV commercials touting the relevant expertise of various plaintiff’s attorneys inspired this article. (HealthNewsDigest.com) – Ever since the Thalidomide catastrophe of the late 1950s, whereby a sedative drug used during pregnancy for morning sickness—largely in Full Article…
Comments Off
Can Actos Prevent Diabetes?
Posted March 30, 2011 on ACHS.com After allegations were made linking the diabetes drug rosiglitazone (Avandia) to an increased risk of heart attack, it was taken off the market in Europe, and its use was severely restricted here by the FDA. Now a new study in the New England Journal of Medicine gives hope that Full Article…
Comments Off
GSK Boss Gets $1.2Million Pay Cut After Poor Year
Posted March 2, 2011 on LSE LONDON, March 2 (Reuters) – GlaxoSmithKline Chief Executive Andrew Witty’s pay was cut by 734, 000 pounds ($1.2 million) to 2.3 million pounds last year after Britain’s biggest drugmaker missed its profit targets. The shortfall followed plunging sales of controversial diabetes pill Avandia, which was withdrawn from the market Full Article…
Comments Off
Avandia to be withdrawn in April – New Zealand
Posted February 16, 2011 on Amanda Cameron Controversial diabetes drug Avandia will be withdrawn from the New Zealand market on 29 April because it raises the risk of having a heart attack. Medsafe has just announced it is making the move after a safety review confirmed the suspected cardiovascular risks of the medicine, meaning its Full Article…
Comments Off
Glaxo Suit on Avandia Heart Attack Death Settled on Trial’s Eve
Posted January 31, 2011 on Bloomberg GlaxoSmithKline Plc said it settled on the eve of trial a lawsuit alleging its Avandia diabetes drug caused a North Carolina man to die of a heart attack, avoiding a jury determination over risks associated with the medicine. The U.K.’s biggest drugmaker resolved the suit by the family of Full Article…
F.D.A. to Restrict Avandia, Citing Heart Risk
Posted September 23, 2010 by NY Times WASHINGTON — In a highly unusual coordinated announcement, drug regulators in Europe and the United States said Thursday that Avandia, the controversial diabetes medicine, would no longer be widely available. The drug’s sales will be suspended entirely in Europe, while patients in the United States will be allowed Full Article…
Comments Off
Slow Death Continues for Avandia
Posted December 26, 2010 on MedPage Today As part of the Year in Review series, MedPage Today reporters are revisiting major news stories and following up with an analysis of the impact of the original report, as well as subsequent news generated by the initial publication. Here’s what’s happened on the rosiglitazone (Avandia) front since Full Article…
Comments Off
FDA Stops Short of Banning Avandia
Posted December 6, 2010 on L. Vine An examination of the history of GlaxoSmithKline’s Avandia (the brand name for the drug rosiglitazone maleate) presents significant doubt about the reliability and safety of pharmaceuticals in general in the United States. The Food and Drug Administration – the regulating body for U.S. pharmaceuticals – has failed to Full Article…
Comments Off
